The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.
Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.
| Metrics | Current | 2024 | 2023 | 2022 |
|---|---|---|---|---|
|
Value
|
31 | 7 | 35 | 26 |
|
Growth
|
1 | 24 | 11 | 55 |
|
Safety
|
100 | 79 | 73 | 84 |
|
Sentiment
|
57 | 65 | 69 | 47 |
|
360° View
|
34 | 25 | 39 | 53 |
| Metrics | Current | 2024 | 2023 | 2022 |
|---|---|---|---|---|
|
Analyst Opinions
|
97 | 97 | 93 | 97 |
|
Opinions Change
|
63 | 70 | 50 | 26 |
|
Pro Holdings
|
n/a | 19 | 39 | 3 |
|
Market Pulse
|
60 | 40 | 47 | 72 |
|
Sentiment
|
57 | 65 | 69 | 47 |
| Metrics | Current | 2024 | 2023 | 2022 |
|---|---|---|---|---|
|
Value
|
31 | 7 | 35 | 26 |
|
Growth
|
1 | 24 | 11 | 55 |
|
|
100 | 79 | 73 | 84 |
|
Combined
|
25 | 13 | 16 | 55 |
| Metrics | Current | 2024 | 2023 | 2022 |
|---|---|---|---|---|
|
Price vs. Sales (P/S)
|
28 | 4 | 78 | 24 |
|
Price vs. Earnings (P/E)
|
15 | 7 | 12 | 3 |
|
Price vs. Book (P/B)
|
58 | 59 | 80 | 59 |
|
Dividend Yield
|
1 | 1 | 1 | 1 |
|
Value
|
31 | 7 | 35 | 26 |
| Metrics | Current | 2024 | 2023 | 2022 |
|---|---|---|---|---|
|
Revenue Growth
|
1 | 4 | 27 | 74 |
|
Profit Growth
|
4 | 92 | 32 | 6 |
|
Capital Growth
|
6 | 6 | 18 | 95 |
|
Stock Returns
|
17 | 53 | 19 | 21 |
|
Growth
|
1 | 24 | 11 | 55 |
| Metrics | Current | 2024 | 2023 | 2022 |
|---|---|---|---|---|
|
Leverage
|
82 | 91 | 94 | 90 |
|
Refinancing
|
90 | 96 | 92 | 94 |
|
Liquidity
|
89 | 4 | 1 | 15 |
|
|
100 | 79 | 73 | 84 |
Discover high‑ranked alternatives to Castle Biosciences and broaden your portfolio horizons.
The Obermatt Advantage
Choose the Obermatt subscription that best fits your needs.
30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.